illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Cellectis
Company logo

Cellectis | Sustainability Performance

https://www.cellectis.com

This biotechnology firm specializes in gene editing technologies. It is involved in research and development for applications in therapeutics and agriculture, focusing on innovative methodologies in genetic engineering.

1999

France

201 - 500 employees

Biotechnology

$25M - 100M in revenue

Not profitable

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#8286
Overall
#427
in France
#165
in Biotechnology

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

198 out of 251

Overview
Environmental
Digital emissions
Governance
TargetsESG scores and Exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
Metabolic Explorer

France, Health Care, Biotechnology


Company logo
Vetoquinol Global

France, Health Care, Pharmaceuticals


Company logo
Servier

France, Health Care, Pharmaceuticals

Market cap

288.0M $, 2026▼8.3% YoY

Revenue

49.0M $, 2024▼81.6% YoY

R&D intensity

69.39% 2024

Digital Emissions


CO2e per visit (g)

Industry benchmark

B/M 0.26 g
0.4 g

B
Environmental ScoreScore B
Green HostingNo
Download Digital Emissions AnalysisPowered by illuminem and Dedalo AI

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Market cap

288.0M $, 2026▼8.3% YoY

Revenue

49.0M $, FY2024▼81.6% YoY

EBITDA

-40.0M $, FY2024▼9.1% YoY

Operating margin

-121% Industry: -380▲774.7% YoY

Revenue & EBITDA

$49.0MFY2024 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

19.1M 2024▼234.8% YoY

Capex

3.0M 2024▼66.7% YoY

Debt/equity ratio

0.7 Industry: 2▼NaN% YoY

R&D intensity

69.4%FY2024

R&D as % of revenue

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Return on invested capital

-16.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

0.0

▼ 50.8%

2022

0.0

▼ 45.8%

2023

0.0

▲ 9.3%

2024

0.2

2031

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Not available

Recycling policy

Not available

Workplace health & safety policy

Available

37%
Independent Directors

7 out of 19 incl. management

Powered by illuminem

Overall score

70

Environment

78

Social

99

Governance

31

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

Sustainability employees


Total sustainability employees

2-3



    Available in
    Scale package

    Access
  • Email

  • Email